[Dizhe Pharmaceutical: Shuvotini launched a global III phase multicenter clinical trial in Shuvotini] Science and Technology Innovation Board Daily reported on the 12th that the company was recently approved by the European Drug Administration (EMA). Approved to conduct a global multicenter, randomized controlled, phase III clinical trial (WU-KONG28) to evaluate suvotinib versus platinum-based first-line chemotherapy for EGFR20 exon insertion (EGFR Exon20ins) mutant advanced non-small cell lung cancer (NSCLC).